Michael Reitermann takes over the operational leadership of the Ascom Group as Delegate of the Board of Directors and interim CEO
MWN-AI** Summary
On September 18, 2025, Ascom Holding AG announced that Michael Reitermann has been appointed as Delegate of the Board of Directors and interim CEO, succeeding Nicolas Vanden Abeele, who has left the company after nearly four years to pursue new opportunities. Reitermann, a board member since 2020, brings over 25 years of experience in the med-tech and life sciences sectors across the USA and Europe, having held executive positions at Siemens Medical Solutions and Siemens Healthineers.
The board's decision aims to maintain strategic momentum while accelerating execution, with a focus on leveraging growth potential in the United States and Canada. An internal and external search for a permanent CEO is underway.
Additionally, the board announced the nomination of Laurent Dubois as the new Chairman of the Board, to be elected at the Annual General Meeting in 2026, succeeding Dr. Valentin Chapero Rueda upon his retirement. Dubois has an extensive background with over three decades of experience in leadership roles across various industries, including consulting and healthcare, and has been serving as CEO of ADB Safegate since 2020.
The Board of Directors also decided to reduce its membership from six to five, effective at the same AGM. This restructuring reflects Ascom's commitment to adapt and drive future growth.
The board expressed gratitude to Vanden Abeele for his contributions during challenging times and emphasized its commitment to ensuring a smooth transition as Reitermann takes the helm. A conference call for analysts and the media is scheduled for the same day as the announcement, reinforcing transparency and engagement with stakeholders.
MWN-AI** Analysis
On September 18, 2025, Ascom Holding AG announced the appointment of Michael Reitermann as the interim CEO and Delegate of the Board of Directors, succeeding Nicolas Vanden Abeele. Reitermann, a seasoned leader with over 25 years in the med-tech sector, particularly in the US and Europe, is expected to steer the company through this transitional phase while the Board initiates a search for a permanent CEO. This leadership shift signals a pivotal moment for Ascom as it aims to enhance its operational focus, especially in North America.
Investors should take a keen interest in this transition, as Reitermann’s extensive experience, notably at Siemens Healthineers, equips him with the expertise to invigorate Ascom's strategic vision. His dual American-German nationality positions him strategically to bridge any gaps in navigating the US market—an area highlighted by the Board as a growth focus.
Moreover, the nomination of Laurent Dubois as the future Chairman adds another layer of stability to the leadership team. Dubois' background, with leadership roles in GE Healthcare and McKinsey, brings further credibility and strategic insight to the Board. The reduction in Board size suggests a move towards streamlined decision-making processes, which could enhance responsiveness and agility in executing business strategies.
Given these developments, market participants should monitor Ascom's execution of its growth strategies closely. The effective management of this leadership transition will be critical. Investors may consider this moment as an opportunity to analyze Ascom's stock, particularly if the interim leadership leads to strong performance indicators in the operational quarters ahead. In light of these leadership changes, it is advisable for investors to stay engaged with Ascom's updates during the upcoming conference call on September 18.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Ad hoc announcement pursuant to Art. 53 LR
Baar, Switzerland, 18 September 2025
Michael Reitermann, Member of the Board of Directors since 2020, and an executive leader with broad experience both in the USA and Europe, has been appointed by the Board of Directors of Ascom Holding AG as Delegate of the Board of Directors and interim CEO. He takes over the operational leadership from Nicolas Vanden Abeele, who decided to leave Ascom after nearly four years as CEO to pursue new professional challenges.
The Board of Directors of Ascom Holding AG nominated Laurent Dubois, Member of the Board of Directors since 2020, as new Chairman of the Board of Directors to be elected at the Annual General Meeting 2026, following the retirement of Dr. Valentin Chapero Rueda.
Michael Reitermann appointed as Delegate of the Board and interim CEO
While pursuing the current strategy, the Board of Directors of Ascom Holding AG targets to accelerate its execution and the exploitation of the growth potential of Ascom, with a special focus on the USA and Canada. Michael Reitermann, Member of the Board of Directors since 2020, has been appointed as Delegate of the Board of Directors and interim CEO to take over the operational leadership of the Ascom Group for a limited time period. In parallel, an internal and external search for a new CEO has been initiated.
Michael Reitermann is an accomplished executive with more than 25 years of commercial and technical expertise in the med-tech/life sciences space in both the USA and Europe. He was the CEO of several entities of Siemens Medical Solutions, and later, the COO and member of the managing board of Siemens Healthineers. Michael Reitermann is living in the USA and has a German/American dual citizenship.
The Board of Directors expresses its sincere appreciation for the departing CEO, Nicolas Vanden Abeele, for his dedicated service during challenging times and for his valuable contributions to the transformation of the Company.
Laurent Dubois nominated as new Chairman of the Board
The Board of Directors nominated Laurent Dubois, Member of the Board since 2020, as new Chairman of the Board to be elected at the Annual General Meeting 2026, following the retirement of Dr. Valentin Chapero Rueda, effective as of the Annual General Meeting 2026.
Laurent Dubois has over three decades of leadership experience in industry, consulting, B2B technology, and healthcare. He was a partner with McKinsey & Co. and later joined GE Healthcare, where he led the global solutions & analytics teams as a member of the Global Executive Team. Since 2020, he has been CEO of ADB Safegate, a Carlyle portfolio company and global leader in airside guidance technology.
Moreover, the Board of Directors decided to reduce its size from six to five members, effective as of the Annual General Meeting 2026.
Note ( www. ascom.com/about-us/who-we-are/board-of-directors)
- CV Michael Reitermann
- CV Laurent Dubois
Conference Call for analysts and media
In the context of this media release, a conference call for analysts and media will take place as follows:
18 September 2025 at 09:00 CET
Dial-in: +41 58 262 07 22 / Code: 030955
Attachment
FAQ**
How does the appointment of Michael Reitermann as interim CEO of Ascom Holding AG ACMLF influence the company's strategy in the USA and Canada moving forward?
What specific qualities or experiences does the Board of Directors see in Laurent Dubois that led to his nomination as the new Chairman of Ascom Holding AG ACMLF?
Can you elaborate on the reasons behind Nicolas Vanden Abeele's departure from Ascom Holding AG ACMLF and how this transition might affect stakeholder confidence?
How will the reduction in the Board's size from six to five members impact the governance and decision-making process at Ascom Holding AG ACMLF?
**MWN-AI FAQ is based on asking OpenAI questions about Ascom Holding AG (OTC: ACMLF).
NASDAQ: ACMLF
ACMLF Trading
-94.65% G/L:
$4.40 Last:
5,000 Volume:
$4.40 Open:
